GlassScriptPhysician profile
Richard J Morse
NPI 1285660084
$1,384.03
in general payments reported to CMS, 2019-2025
20 companies · $207 in 2025
The $207 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $56.96 · 2021: $160 · 2022: $213 · 2023: $350 · 2024: $163 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $212.95 | 2019-2025 | |
| Cranial Technologies, INC | $190.35 | 2020-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $182.02 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Glaxosmithkline, LLC. | $161.84 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $140.54 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $78.09 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $63.14 | 2019-2020 | |
| Alk-Abello, INC | $57.64 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $40.47 | 2023 | Flumist Quadrivalent |
| Corium, LLC | $38.01 | 2022 | |
| Biofire Diagnostics, LLC | $33.96 | 2019 | |
| Seqirus USA INC | $32.52 | 2023-2024 | Flucelvax Quadrivalent, Flucelvax |
| Kaleo, INC. | $27.80 | 2019-2021 | |
| Phadia US INC. | $27.42 | 2025 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.42 | 2019 | |
| Aytu Biopharma, INC. | $17.41 | 2021 | |
| Hikma Pharmaceuticals USA | $16.27 | 2023 | Ryaltris |
| Abbvie INC. | $15.25 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.